Latest Derivatives News

Cambium Bio has struck a licensing deal with Keke Medtech to commercialise its fibrin biologic in dental applications, unlocking new markets and non-dilutive funding.

Enova Mining has completed its first systematic geochemical sampling at the Santo Antônio do Jacinto project in Brazil, marking a significant step in exploring rare earth elements in a promising greenfield area. Assay results are expected by the end of September, setting the stage for targeted follow-up exploration.

Fat Prophets Global Contrarian Fund Ltd has reported a robust 56% increase in net profit for the year ended 30 June 2025, driven by strong investment returns and a leveraged global equity portfolio. The company also declared a fully franked special dividend, reflecting confidence in its ongoing performance.

TPC Consolidated Limited reported a robust 20.9% increase in revenue to $193.1 million for FY25, driven by growth in electricity and gas services. However, net profit after tax plunged 94.4% to $0.3 million, reflecting the impact of volatile wholesale electricity prices and rising costs, while a proposed acquisition awaits regulatory approval.

Kingsland Minerals has achieved a breakthrough with 99.97% purified spherical graphite from its Leliyn project, advancing its position in the EV battery supply chain. The company is on track to complete its scoping study next month, with downstream processing partnerships underway.

Waypoint REIT reported steady distributable earnings of $55.6 million for the first half of 2025, supported by robust property valuations and disciplined capital management. Despite flat earnings, statutory net profit surged nearly 47%, reflecting significant valuation gains.

PYC Therapeutics has reported promising safety data from the initial phase of its clinical trial for PYC-003, an RNA therapy targeting the root cause of Polycystic Kidney Disease. The findings, presented at the ANZSN conference, highlight the drug’s tolerability in healthy volunteers, paving the way for further clinical development.

Mesoblast Limited has reported its FY2025 results, highlighting the FDA approval and US commercial launch of Ryoncil, its first mesenchymal stromal cell therapy, alongside a $102.1 million net loss and $161.6 million in cash reserves.

Regal Investment Fund reported a sharp 78% drop in operating profit for FY25 but maintained steady performance slightly above the RBA Cash Rate. The fund bolstered its position with a $104 million capital raise and extended its on-market buy-back program through mid-2026.

Identitii Limited reported a modest 4% revenue increase to $777,542 for FY25, yet its net loss expanded by 8% to $3.82 million, driven by lower investment gains. The company strengthened its cash position through successful capital raising and ongoing cost reductions.

The 2025 annual report for SPDR Core Equity ETFs confirms compliance with accounting standards and provides detailed unitholder data, underscoring the funds' robust governance and market position.

DigiCo Infrastructure REIT confirms its FY25 EBITDA slightly exceeded IPO guidance and aligned with analyst forecasts, attributing recent share price declines to the absence of FY26 earnings guidance.